{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(1)"],"submitter":["Banus-Mulet A"],"pubmed_abstract":["Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are chronic myeloid clonal neoplasms. To date, the only potentially curative therapy for these disorders remains allogeneic hematopoietic progenitor cell transplantation (HCT), although patient eligibility is limited due to high morbimortality associated with this procedure coupled with advanced age of most patients. Dopamine receptors (DRs) and serotonin receptors type 1 (HTR1s) were identified as cancer stem cell therapeutic targets in acute myeloid leukemia. Given their close pathophysiologic relationship, expression of HTR1s and DRs was interrogated in MDS and CMML. Both receptors were differentially expressed in patient samples compared to healthy donors. Treatment with HTR1B antagonists reduced cell viability."],"journal":["Scientific reports"],"pagination":["13883"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6141614"],"repository":["biostudies-literature"],"pubmed_title":["Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML."],"pmcid":["PMC6141614"],"pubmed_authors":["Etxabe A","Torrente MA","Nomdedeu M","Banus-Mulet A","Palomo L","Sole F","Diaz-Beya M","Risueno RM","Cornet-Masana JM","Esteve J","Lara-Castillo MC","Nomdedeu B"],"additional_accession":[]},"is_claimable":false,"name":"Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.","description":"Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) are chronic myeloid clonal neoplasms. To date, the only potentially curative therapy for these disorders remains allogeneic hematopoietic progenitor cell transplantation (HCT), although patient eligibility is limited due to high morbimortality associated with this procedure coupled with advanced age of most patients. Dopamine receptors (DRs) and serotonin receptors type 1 (HTR1s) were identified as cancer stem cell therapeutic targets in acute myeloid leukemia. Given their close pathophysiologic relationship, expression of HTR1s and DRs was interrogated in MDS and CMML. Both receptors were differentially expressed in patient samples compared to healthy donors. Treatment with HTR1B antagonists reduced cell viability.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2026-06-14T04:07:39.528Z","creation":"2025-05-18T13:24:29.289Z"},"accession":"S-EPMC6141614","cross_references":{"pubmed":["30224768"],"doi":["10.1038/s41598-018-32306-4"]}}